Additionally, the potential benefits of GLP-1RAs and dual GIP/GLP-1RAs in patients with HF or ASCVD but without overweight/obesity remain unexplored and represent an important avenue for future research. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.